Phenylboronic acid modified lipid nanocarriers mediated co-delivery of immunocytokine TRAIL and gamma-secretase inhibitor to triple negative breast cancer cells and cancer stem cells

Triple negative breast cancer (TNBC) is an aggressive form of breast cancer with high rates of tumor relapse and metastasis. The existing drugs for treatment of TNBC are unable to target the cells of origin (breast cancer stem cells) of TNBC. TNF-α related apoptosis inducing ligand (TRAIL) has prope...

Full description

Saved in:
Bibliographic Details
Published in:Medical hypotheses 2021-12, Vol.157, p.110716-110716, Article 110716
Main Authors: Pindiprolu, Sai Kiran S.S., Avasarala, Harani, Dinakaran, Sathis Kumar
Format: Article
Language:English
Subjects:
Apoptosis
Cancer stem cells
Death receptors
Gamma-secretase
Metastasis
Notch
Phenyl boronate
Triple negative breast cancer
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Triple negative breast cancer (TNBC) is an aggressive form of breast cancer with high rates of tumor relapse and metastasis. The existing drugs for treatment of TNBC are unable to target the cells of origin (breast cancer stem cells) of TNBC. TNF-α related apoptosis inducing ligand (TRAIL) has propensity to target TNBC cells including cancer stem cells. However, resistance to TRAIL due to activation of anti-apoptotic mechanisms is a limitation for TRAIL based anticancer therapy for TNBC. In the present study we propose an hypothesis for effective targeting of triple negative breast cancer by overcoming TRAIL resistance.
ISSN:0306-9877
1532-2777
DOI:10.1016/j.mehy.2021.110716